Endophthalmitis Cultures (PROSPER)
This study has been terminated.
Information provided by (Responsible Party):
Stephen J. Kim, MD, Vanderbilt University
First received: December 19, 2011
Last updated: February 20, 2017
Last verified: February 2017
The intent of this surveillance study will be to obtain written permission from patients with bacterial endophthalmitis in order to compare sterilization rates of their cultured bacterial isolates to standard therapy (vancomycin and ceftazidime) versus combination therapy with vancomycin, ceftazidime, and moxifloxacin.
- Cultured bacterial isolates will demonstrate faster in vitro sterilization rates with combination treatment (vancomycin, ceftazidime, and moxifloxacin) compared to "standard therapy" with vancomycin and ceftazidime.
- Longitudinal analysis of resistance patterns of cultured isolates will show increasing rates of multi-antibiotic resistance.
||Observational Model: Case-Only
Time Perspective: Prospective
||Prospective Surveillance of Patients With Endophthalmitis for Multi-antibiotic Resistance (PROSPER) Study
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||April 2016 (Final data collection date for primary outcome measure)
Adult patients over 18 years of age presenting with endophthalmitis and able to sign consent.
|Ages Eligible for Study:
||18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Vanderbilt Eye Institute
- all adult patients age 18 or greater presenting with bacterial endophthalmitis to the Vanderbilt Eye Institute and who grow positive cultures
- Patients < 18 years of age or those patients without positive cultures
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01496794
|Vanderbilt Eye Institute
|Nashville, Tennessee, United States, 37232 |
||Stephen J Kim, MD
||Vanderbilt University Medical Center
||Stephen J. Kim, MD, Assistant Professor of Ophthalmology, Vanderbilt University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 19, 2011
||February 20, 2017
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 25, 2017